Stability studies to support shipping and distribution of drug products by ComplianceOnline

VIEWS: 28 PAGES: 2

More Info
									Study to Support Shipping and Distributing Pharmaceutical Products
Learn the stability studies which need to be done to support shipping and distribution of drugs.

Description


Why Should You Attend:


Drug Product must maintain its identity, strength, quality and purity throughout its expiration.
Physical, chemical and biological data are influenced by various environmental factors such as
temperature, humidity and light. In current manufacturing environment, products can be shipped and
distributed across different climatic zones. Seasonal changes as well as types of transportation can
greatly affect the supply chain of the products.


This webinar will outline stability studies to support shipping and distribution of drug products. Upon
completion of this session, attendees will learn key factors that would affect the shipping and
distribution of drug products. you will understand the product stability profile, typical environmental
conditions for storage and anticipating environmental extremes for distribution. These data will be
necessary to design shipping condition in order to maintain quality of the drug product through expiry.


Areas Covered in the Seminar:


        Goal of stability studies.
        Warning letters and observations on shipping and distribution practices.
        Short term excursion study.
        Thermal cycling study.
        Analytical testing for these studies.


Who Will Benefit:


        Pharmaceutical scientists
        Manufacturers or raw material and ingredients
        Analysts and lab managers
        QA managers and personnel
        Regulatory affairs
Instructor Profile:


Kim Huynh-Ba, has almost 25 years of experience in analytical development, project management,
strategic drug development and stability sciences. She is the Executive Director of Pharmalytik, where
she provides consulting and training services to pharmaceutical companies including companies
operating under FDA’s Consent Decree on harmonization and optimization of analytical best practices.
Prior to this position, she was the Director of Pharmacopeial Education Department of U.S.
Pharmacopeia (USP), where she was responsible for their education programs worldwide. Kim has
held several technical and quality positions at Astra Zeneca (formerly ICI Americas), DuPont Merck,
DuPont Pharmaceuticals, Bristol Myers Squibb and Wyeth Vaccines. Kim is also a short course
instructor on cGMP compliance and quality topics for several global organizations such as American
Chemical Society (ACS), American Association of Pharmaceutical Scientists (AAPS), Pittsburgh
Conference, and many other international training groups. She is an Adjunct Professor at Temple
University-School of Pharmacy, Widener University and Illinois Institute of Technology teaching
pharmaceutical analyses and analytical chemistry graduate courses.


Kim serves on the Executive Committee of Governing Board of Eastern Analytical Symposium (EAS)
and will be their 2013 President. Kim is a recipient of the 2008 Service Award of Analysis and
Pharmaceutical Quality Section and 2008 Recognition Award of Regulatory Section of AAPS. She also
received the 2001 DuPont Pharmaceutical Company Asian American Leadership Award.


Kim has authored numerous technical publications and book chapters and has spoken extensively,
both domestic and globally, in the compliance and quality areas. She is the editor of the “Handbook of
Stability Testing in Pharmaceutical Development: Regulations, Methodologies and Best Practices”
(2008) and “Pharmaceutical Stability Testing to Support Global Markets” (2010).

								
To top